


AMENDMENT TO THE CLAIMS

Claims 1-34 (cancelled).

Claim 35 (new). A combination, comprising synergistic pain alleviating amounts of gabapentin and an NMDA receptor antagonist in a weight/weight ratio of from 1:50 to 50:1, respectively.

 **Claim 36 (new).** A combination, comprising synergistic pain alleviating amounts of pregabalin and an NMDA receptor antagonist in a weight/weight ratio of from 1:50 to 50:1, respectively.

Claim 37 (new). A pharmaceutical composition, comprising synergistic pain alleviating amounts of gabapentin and an NMDA receptor antagonist in a weight/weight ratio of from 1:50 to 50:1, respectively, together with a pharmaceutically acceptable carrier.

Claim 38 (new). A pharmaceutical composition, comprising synergistic pain alleviating amounts of pregabalin and an NMDA receptor antagonist in a weight/weight ratio of from 1:50 to 50:1, respectively, together with a pharmaceutically acceptable carrier.

Claim 39 (new). A method for treating acute pain in a patient in need of treatment, comprising administering to the patient an acute pain relieving amount of the pharmaceutical composition according to Claim 37 or 38.

Claim 40 (new). A method for treating chronic pain in a patient in need of treatment, comprising administering to the patient an chronic pain relieving amount of the pharmaceutical composition according to Claim 37 or 38.

Claim 41 (new). A method for treating inflammatory pain in a patient in need of treatment, comprising administering to the patient an inflammatory pain relieving amount of the pharmaceutical composition according to Claim 37 or 38.

B2
amt

✓